Afuco™ Anti-human Cfc1 Adcc Theraputic Antibody (biib015), Adcc Enhanced

Country: United States
Founded Year: 2005
Contact: Jerry Carter

Anti-CFC1 ADCC Enhanced Antibody (BIIB015) is an ADCC enhanced antibody produced by our Afuco™ platform. BIIB015 is an immunoconjugate created for the treatment of solid tumours and is currently in Phase I of clinical evaluation. BIIB015 consists of a humanised monoclonal antibody against the Cripto protein carrying a payload, via a hindered disulphide linker, of the maytansinoid derivative, DM4. BIIB015 shows robust activity with results ranging from>50% tumour inhibition to complete tumour regression. In addition, BIIB015 can be combined with standard of care chemotherapeutics for enhanced efficacy.

https://www.creativebiolabs.net/Anti-CFC1-ADCC-Enhanced-Antibody-BIIB015-20457.htm